Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This is a review of the topic of fibrinolysis contributed by authors who are specialized in the clinical and basic studies of this topic. These include: the endothelial receptor of tissue plasminogen activator, by Dr. Katherine Hajjar; regulation of S100 by pml-rar-alpha oncoprotein, by Dr. O’Connell; receptor of urokinase type plasminogen activator, by Dr. M. Ploug et al.; tissue plasminogen activator induction in purjinjen neuron, by Dr. Seeds; fibrinolysis from the blood to the brain, by Dr. Robert Metcalf; tissue plasminogen activator induces the opening of the blood–brain barrier, by Dr. M. Yepes; fibrinolysis shutdown in trauma: a historical review and clinical application, by Drs. Hunter Moore and Ernest Moore; fibrinolysis in immunity, by Drs. K. Kolev and Robert Medcalf; the role of plasminogen activator inhibitor 1, by Drs. M. Erin, A.E. Boe, and E.A. Klyachko; and finally, persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients, by J.P. Meizoso.

Research & information: general --- Biology, life sciences --- COVID-19 --- fibrinolysis --- renin-aldosterone-angiotensin-system (RAAS) --- plasminogen activator inhibitor 1 (PAI-1) --- urokinase plasminogen activator --- urokinase plasminogen activator receptor --- plasminogen activator inhibitor-1 --- acute lung injury and repair and pleural injury and pleural organization --- PAI-1 --- cardiovascular disease --- cancer --- inflammation --- fibrosis --- aging --- obstructive sleep apnoea --- OSA --- coagulation --- platelets --- brown adipose tissue --- obesity --- plasminogen activation --- immune response --- thrombin activatable fibrinolysis inhibitor --- TAFI --- proCPU --- proCPB --- proCPR --- carboxypeptidase --- uPA --- uPAR --- PA system --- tissue-type plasminogen activator (tPA) --- urokinase-type plasminogen activator (uPA) --- neurodegeneration --- thrombin --- shear --- clot retraction --- Factor XIII --- clot stability --- NETs --- plasmin --- plasminogen activator --- PAI-2 --- antiplasmin

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This is a review of the topic of fibrinolysis contributed by authors who are specialized in the clinical and basic studies of this topic. These include: the endothelial receptor of tissue plasminogen activator, by Dr. Katherine Hajjar; regulation of S100 by pml-rar-alpha oncoprotein, by Dr. O’Connell; receptor of urokinase type plasminogen activator, by Dr. M. Ploug et al.; tissue plasminogen activator induction in purjinjen neuron, by Dr. Seeds; fibrinolysis from the blood to the brain, by Dr. Robert Metcalf; tissue plasminogen activator induces the opening of the blood–brain barrier, by Dr. M. Yepes; fibrinolysis shutdown in trauma: a historical review and clinical application, by Drs. Hunter Moore and Ernest Moore; fibrinolysis in immunity, by Drs. K. Kolev and Robert Medcalf; the role of plasminogen activator inhibitor 1, by Drs. M. Erin, A.E. Boe, and E.A. Klyachko; and finally, persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients, by J.P. Meizoso.

Research & information: general --- Biology, life sciences --- COVID-19 --- fibrinolysis --- renin-aldosterone-angiotensin-system (RAAS) --- plasminogen activator inhibitor 1 (PAI-1) --- urokinase plasminogen activator --- urokinase plasminogen activator receptor --- plasminogen activator inhibitor-1 --- acute lung injury and repair and pleural injury and pleural organization --- PAI-1 --- cardiovascular disease --- cancer --- inflammation --- fibrosis --- aging --- obstructive sleep apnoea --- OSA --- coagulation --- platelets --- brown adipose tissue --- obesity --- plasminogen activation --- immune response --- thrombin activatable fibrinolysis inhibitor --- TAFI --- proCPU --- proCPB --- proCPR --- carboxypeptidase --- uPA --- uPAR --- PA system --- tissue-type plasminogen activator (tPA) --- urokinase-type plasminogen activator (uPA) --- neurodegeneration --- thrombin --- shear --- clot retraction --- Factor XIII --- clot stability --- NETs --- plasmin --- plasminogen activator --- PAI-2 --- antiplasmin --- COVID-19 --- fibrinolysis --- renin-aldosterone-angiotensin-system (RAAS) --- plasminogen activator inhibitor 1 (PAI-1) --- urokinase plasminogen activator --- urokinase plasminogen activator receptor --- plasminogen activator inhibitor-1 --- acute lung injury and repair and pleural injury and pleural organization --- PAI-1 --- cardiovascular disease --- cancer --- inflammation --- fibrosis --- aging --- obstructive sleep apnoea --- OSA --- coagulation --- platelets --- brown adipose tissue --- obesity --- plasminogen activation --- immune response --- thrombin activatable fibrinolysis inhibitor --- TAFI --- proCPU --- proCPB --- proCPR --- carboxypeptidase --- uPA --- uPAR --- PA system --- tissue-type plasminogen activator (tPA) --- urokinase-type plasminogen activator (uPA) --- neurodegeneration --- thrombin --- shear --- clot retraction --- Factor XIII --- clot stability --- NETs --- plasmin --- plasminogen activator --- PAI-2 --- antiplasmin